Critical News Coverage Extremely Likely to Impact AstraZeneca (NYSE:AZN) Stock Price

Media headlines about AstraZeneca (NYSE:AZN) have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 6,000 news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -2.78 on their scale. InfoTrie also gave news articles about the company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have impacted AstraZeneca’s ranking:

AZN stock opened at $43.72 on Tuesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.75 and a current ratio of 0.95. AstraZeneca has a 52 week low of $35.30 and a 52 week high of $46.22. The firm’s fifty day moving average is $44.09 and its 200 day moving average is $41.55. The firm has a market cap of $115.79 billion, a P/E ratio of 25.27, a P/E/G ratio of 1.49 and a beta of 0.47.

AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, July 25th. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.43. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The company had revenue of $5.72 billion for the quarter, compared to analyst estimates of $5.57 billion. During the same quarter last year, the firm earned $0.69 EPS. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. As a group, analysts forecast that AstraZeneca will post 1.8 EPS for the current year.

Several analysts have recently weighed in on AZN shares. Zacks Investment Research cut shares of AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 3rd. Argus raised their price objective on shares of AstraZeneca to $50.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. ValuEngine cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. DZ Bank lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Tuesday, September 3rd. Finally, HSBC reaffirmed a “sell” rating on shares of AstraZeneca in a report on Thursday, October 17th. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the company. AstraZeneca presently has a consensus rating of “Hold” and an average price target of $46.53.

In other news, major shareholder Plc Astrazeneca purchased 425,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were acquired at an average price of $19.00 per share, with a total value of $8,075,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Trading Stocks – What are percentage gainers?

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.